Nexstim Plc has won a tender process resulting in a procurement decision for an NBS 5 System in Finland. The customer is new to Nexstim in psychiatric applications. This specific NBS (Navigated Brain Stimulation) System 5 includes both diagnostic and therapeutic capabilities.

This means that the system is suitable for cross-departmental use with CE markings for presurgical mapping of the motor cortex of the brain as well as for the treatment of severe depression and chronic neuropathic pain. rTMS (repetitive transcranial magnetic stimulation) treatments with systems are indicated for adults that have failed to achieve satisfactory improvement from prior antidepressant medication in the current depression episode. Based on the data Nexstim has gathered, treatments for these patients have been highly effective with nearly 50% achieving clinical remission and more than three in four patients obtaining a clinical response.

With the combined system option, the company can add to this value and answer to customers? versatile needs.